{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:29:38Z","timestamp":1766107778919,"version":"3.48.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109268","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:42:43Z","timestamp":1763646163000},"page":"109268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and anticancer evaluation of new Phenylpyrazolone derivatives: Dual JAK1\/ JAK2 inhibition, apoptosis-inducing activity, and molecular modelling studies"],"prefix":"10.1016","volume":"167","author":[{"given":"Samar I.","family":"Faggal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kholoud I.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed R.","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed M.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr M.","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram Hifny Abd","family":"El-Haleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109268_bb0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ebiom.2015.05.022","article-title":"Is Cancer a genetic disease or a metabolic disease?","volume":"2","author":"Wishart","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bioorg.2025.109268_bb0010","article-title":"Variation in effects of Non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.109268_bb0015","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1100\/2011\/373876","article-title":"Human leukocyte antigen class i and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma","volume":"11","author":"Lu","year":"2011","journal-title":"Sci. World J."},{"key":"10.1016\/j.bioorg.2025.109268_bb0020","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.109268_bb0025","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1080\/17568919.2024.2342668","article-title":"Thiazolation of phenylthiosemicarbazone to access new thiazoles\u00a0: anticancer activity and molecular docking","volume":"16","author":"Elgammal","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0030","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1021\/acsmedchemlett.6b00247","article-title":"Design, synthesis, and antitumor evaluation of 4-amino-(1H)-pyrazole derivatives as JAKs inhibitors","volume":"7","author":"Liang","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109268_bb0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.109268_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114760","article-title":"Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential","volume":"193","author":"Tzeng","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1507621","article-title":"Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential","volume":"12","author":"Li","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2017.05.033","article-title":"Jak stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition","volume":"451","author":"Groner","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0060","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3892\/ol.2021.12613","article-title":"Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1\/2-STAT1-Mcl-1 axis","volume":"21","author":"Li","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2025.109268_bb0065","first-page":"979","article-title":"JAK\/STAT pathways in cytokine Signaling and myeloproliferative disorders: approaches for targeted therapies, genes","volume":"1","author":"Jatiani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.109268_bb0070","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109268_bb0075","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/leu.2011.148","article-title":"SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies","volume":"25","author":"Hart","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.109268_bb0080","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3324\/haematol.2017.174482","article-title":"Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment","volume":"103","author":"Lam","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2025.109268_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.666725","article-title":"Heterocyclic compounds: pharmacology of pyrazole Analogs from rational structural considerations","volume":"12","author":"Costa","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0090","doi-asserted-by":"crossref","first-page":"21805","DOI":"10.3390\/ijms141121805","article-title":"New potential antitumor pyrazole derivatives: synthesis and cytotoxic evaluation","volume":"14","author":"Nitulescu","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109268_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103470","article-title":"Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line","volume":"97","author":"Bennani","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0100","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1021\/jm3012239","article-title":"Discovery of potent and selective pyrazolopyrimidine Janus kinase 2 inhibitors","volume":"55","author":"Hanan","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0105","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-016-3012-z","article-title":"Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib","volume":"77","author":"Bryan","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107985","article-title":"Advances in structural identification of some thieno[2,3-d]pyrimidine scaffolds as antitumor molecules: synthetic approaches and control programmed cancer cell death potential","volume":"154","author":"Mghwary","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0115","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1021\/acs.jmedchem.4c00197","article-title":"Functional and structural characterization of clinical-stage Janus kinase 2 inhibitors identifies determinants for drug selectivity","volume":"67","author":"Miao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0120","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bmcl.2019.04.008","article-title":"Discovery of a class of highly potent Janus kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling","volume":"29","author":"Zak","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109268_bb0125","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ddr.22060","article-title":"Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone-based derivatives as DHFR inhibitors","volume":"84","author":"Osman","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ddr.22037","article-title":"Coumarin derivatives with potential anticancer and antibacterial activity: design, synthesis, VEGFR-2 and DNA gyrase inhibition, and in silico studies","volume":"84","author":"Emam","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0135","article-title":"Design, synthesis, and anticancer evaluation of new quinazoline hybrids: DNA intercalation, topoisomerase II\u03b1 inhibition, and in silico studies","volume":"164","author":"Hassan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109003","article-title":"Design and synthesis of new Thieno[2,3-d]pyrimidine-based derivatives as anti-breast cancer: biological evaluation, PIM-1 kinase inhibition, and in silico studies","volume":"165","author":"Sayed","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0145","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1039\/D5MD00139K","article-title":"Novel furo[2,3-d]pyrimidine derivatives as PI3K\/AKT dual inhibitors: design, synthesis, biological evaluation, and molecular dynamics simulation","volume":"16","author":"Reheim","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108549","article-title":"Synthesis and evaluation of antibacterial activity of new thieno[2,3-d]pyrimidine hybrid compounds targeting dihydropteroate synthase to combat antibiotic resistance","volume":"161","author":"Hassan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0155","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ddr.22088","article-title":"Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3-d]pyrimidine derivatives as EGFR inhibitors","volume":"84","author":"Sayed","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0160","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ddr.22058","article-title":"Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3- d ]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K\/AKT\/mTOR signaling pathway","volume":"84","author":"Seif","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70007","article-title":"New S -substituted-3-phenyltetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B-RAF signaling pathway","volume":"85","author":"Seif","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202400077","article-title":"Design, synthesis, and molecular docking of novel miscellaneous chalcones as p38\u03b1 mitogen-activated protein kinase inhibitors","volume":"21","author":"Zeid","year":"2024","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2025.109268_bb0175","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1039\/D4MD00462K","article-title":"Design, synthesis, and biological evaluation of novel thiazole derivatives as PI3K\/mTOR dual inhibitors","volume":"15","author":"Faggal","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118286","article-title":"Design, synthesis, and anticancer evaluation of new pyrazolo[3,4-d]pyrimidine-based derivatives: CDK2 inhibition, apoptosis-inducing activity, molecular modelling studies","volume":"128","author":"Hassan","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0185","article-title":"Thieno[2,3-d]pyrimidine derivatives as topoisomerase II inhibitors: design, synthesis, anticancer evaluation, and in silico studies","volume":"164","author":"Hassan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0190","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1039\/D3MD00476G","article-title":"Novel pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity","volume":"14","author":"Abdelhamed","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0195","first-page":"2660","article-title":"Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors, bioorganic","volume":"24","author":"Liang","year":"2016","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900308","article-title":"Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase","volume":"353","author":"Shabaan","year":"2020","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.109268_bb0205","first-page":"19","article-title":"Pyrazol-5-ones: tautomerism, synthesis and reactions","volume":"1","author":"Metwally","year":"2012","journal-title":"Int. J. Mod. Org. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2478\/v10007-012-0007-0","article-title":"Synthesis and potential biological activity of some novel 3-[(N-substituted indol-3-yl)methyleneamino]-6-amino-4-aryl-pyrano(2,3-c)pyrazole-5-carbonitriles and 3,6-diamino-4-(N-substituted indol-3-yl)pyrano(2,3-c)pyrazole-5-carbonitriles","volume":"62","author":"Mandour","year":"2012","journal-title":"Acta Pharma."},{"key":"10.1016\/j.bioorg.2025.109268_bb0215","first-page":"1671","article-title":"Synthesis and bioactivity evaluation of pyrazolone derivatives","volume":"49","author":"Mariappan","year":"2010","journal-title":"Indian J. Chem. - sect. B org. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140702","article-title":"Novel 4-((3-fluorobenzyl)oxy)benzohydrazide derivatives as promising anti-prostate cancer agents: Synthesis, characterization and in vitro & in silico biological activity studies","volume":"1322","author":"\u00c7ak\u0131r","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109268_bb0225","article-title":"3-amino-thiophene-2-carbohydrazide derivatives as anti Colon Cancer agents: synthesis, Characterization, In-Silico and In-Vitro Biological Activity Studies","volume":"8","author":"\u015eenol","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109268_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116832","article-title":"Bioisosteric replacement of the carboxylic acid group in hepatitis-C virus NS5B thumb site II inhibitors: phenylalanine derivatives","volume":"279","author":"Camci","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0235","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tet.2014.11.022","article-title":"Useful four-carbon synthons en route to monastrol analogs","volume":"71","author":"Abdou","year":"2015","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2025.109268_bb0240","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109268_bb0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0250","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2025.109268_bb0255","first-page":"2515","article-title":"Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production","volume":"51","author":"Vistica","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0260","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.109268_bb0265","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1039\/D4RA08866B","article-title":"Recent advances in the synthesis of anticancer pyrazole derivatives using microwave, ultrasound, and mechanochemical techniques","volume":"15","author":"Becerra","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109268_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105137","article-title":"Novel thienopyrimidine-aminothiazole hybrids: design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition","volume":"114","author":"El-Dash","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0275","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejmech.2015.07.035","article-title":"Synthesis and biological evaluation of a novel betulinic acid derivative as an inducer of apoptosis in human colon carcinoma cells (HT-29)","volume":"102","author":"Chakraborty","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202303108","article-title":"The suppressive effect of novel hydrazones-tethered Imidazoles in HCT-116 and HT-29 colorectal Cancer cells: synthesis, Biological Activity and Molecular Modeling Studies","volume":"9","author":"Keke\u00e7muhammed","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109268_bb0285","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2025.109268_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.951","article-title":"Discriminating between apoptosis, necrosis, necroptosis, and ferroptosis by microscopy and flow cytometry","volume":"3","author":"Costigan","year":"2023","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.bioorg.2025.109268_bb0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0300","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100454","article-title":"Upregulation of BAX and caspase-3, as well as downregulation of Bcl-2 during treatment with indeno[1,2- b ]quinoxalin derivatives, mediated apoptosis in human cancer cells","volume":"355","author":"Fayed","year":"2022","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.109268_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103329","article-title":"Synthesis, characterization, anti-proliferative properties and DNA binding of benzochromene derivatives: increased Bax\/Bcl-2 ratio and caspase-dependent apoptosis in colorectal cancer cell line","volume":"93","author":"Ahagh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0310","doi-asserted-by":"crossref","first-page":"19204","DOI":"10.1039\/D5RA02046H","article-title":"Targeting apoptotic pathways in cancer: design, synthesis, and molecular docking studies of 1,3,5-trisubstituted-1 H -pyrazole derivatives with Bcl-2 inhibition and DNA damage potential","volume":"15","author":"Temirak","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109268_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2025.109268_bb0320","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1007\/s12035-023-03433-5","article-title":"A review on caspases: key regulators of biological activities and apoptosis","volume":"60","author":"Sahoo","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0325","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1007\/s00044-017-1998-3","article-title":"Identification of potential type 4 cAMP phosphodiesterase inhibitors via 3D pharmacophore modeling, virtual screening, DFT and structural bioisostere design","volume":"26","author":"Gogoi","year":"2017","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0330","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.3390\/molecules27144606","article-title":"Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: in vitro anticancer and VEGFR-2 inhibitory effects","volume":"27","author":"Elkaeed","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109268_bb0335","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s11030-021-10211-9","article-title":"Identification of potential plant - based inhibitor against viral proteases of SARS - CoV - 2 through molecular docking, MM - PBSA binding energy calculations and molecular dynamics simulation","volume":"25","author":"Gogoi","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2025.109268_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105526","article-title":"Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors\u00a0: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation","volume":"146","author":"Raafat","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bioorg.2025.109268_bb0345","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.109268_bb0350","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural insights into JAK2 inhibition by Ruxolitinib, Fedratinib, and derivatives thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0355","series-title":"Crystal structure of human janus kinase 2 (jak2) and uses thereof, United States Patent. Pat. No US 7,593,820 B2","first-page":"831","volume":"16","author":"Structure","year":"2009"},{"key":"10.1016\/j.bioorg.2025.109268_bb0360","first-page":"971","article-title":"Studies in the Vilsmeier\u2014Haack reaction: part XII. Synthesis of the 2-phenylpyrazolo[3,4-b]quinoline system","volume":"14","author":"Purnaprajna","year":"1976","journal-title":"Indian J. Chem. Sect B."},{"key":"10.1016\/j.bioorg.2025.109268_bb0365","series-title":"The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985\u20131995, in: Anticancer Drug Dev. Guid. Preclin. Screening, Clin. Trials, Approv","first-page":"23","author":"Boyd","year":"1997"},{"key":"10.1016\/j.bioorg.2025.109268_bb0370","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bioorg.2018.07.008","article-title":"Novel benzotriazole N-acylarylhydrazone hybrids: design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition","volume":"80","author":"Kassab","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0375","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2174\/138945011794751528","article-title":"The use of structural biology in Janus kinase targeted drug discovery","volume":"12","author":"Alicea-Velazquez","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2025.109268_bb0380","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1039\/D0MD00436G","article-title":"Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives","volume":"12","author":"Sanachai","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0385","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/14756366.2021.1901089","article-title":"Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers","volume":"36","author":"Kassab","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0390","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bioorg.2025.109268_bb0395","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.3390\/molecules28145548","article-title":"Novel 2-Sulfanylquinazolin-4(3H)-one derivatives as multi-kinase inhibitors and apoptosis inducers: A synthesis, Biological Evaluation, and Molecular Docking Study","volume":"28","author":"Altharawi","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109268_bb0400","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/plants11172192","article-title":"Potential apoptotic activities of Hylocereus undatus Peel and pulp extracts in MCF-7 and Caco-2 Cancer cell lines","volume":"11","author":"Salam","year":"2022","journal-title":"Plants"},{"key":"10.1016\/j.bioorg.2025.109268_bb0405","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/14756366.2018.1564046","article-title":"Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR\/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis","volume":"34","author":"Maher","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0410","doi-asserted-by":"crossref","first-page":"38832","DOI":"10.1021\/acsomega.4c04924","article-title":"Design, synthesis, and in vitro cytotoxic studies of some novel arylidene-Hydrazinyl-thiazoles as anticancer and apoptosis-inducing agents","volume":"9","author":"Aggarwal","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.109268_bb0415","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/cbdd.13667","article-title":"Comparative QSAR model generation using pyrazole derivatives for screening Janus kinase-1 inhibitors","volume":"95","author":"Sarithamol","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.109268_bb0420","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13065-023-01110-1","article-title":"Lead generation of UPPS inhibitors targeting MRSA: Using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamic simulations","volume":"18","author":"Qandeel","year":"2024","journal-title":"BMC Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0250-474X.103846","article-title":"Ligand-based Pharmacophore Modeling\u00a0; Atom-based 3D-QSAR Analysis and Molecular Docking Studies of Phosphoinositide-Dependent Kinase-1 Inhibitors","volume":"74","author":"Kirubakaran","year":"2012","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.109268_bb0430","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1007\/s00044-013-0571-y","article-title":"The discovery of potential cyclin A \/ CDK2 inhibitors\u00a0: a combination of 3D QSAR pharmacophore modeling, virtual screening, and molecular docking studies","volume":"22","author":"Ece","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.109268_bb0435","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.109268_bb0440","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jcc.21600","article-title":"Software news and updates Gabedit \u2014 A graphical user Interface for computational chemistry Softwares","volume":"32","author":"Allouche","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2025.109268_bb0445","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13321-019-0362-7","article-title":"DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism","volume":"11","author":"Bell","year":"2019","journal-title":"J. Cheminform."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:23:44Z","timestamp":1766107424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825011484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":89,"alternative-id":["S0045206825011484"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109268","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and anticancer evaluation of new Phenylpyrazolone derivatives: Dual JAK1\/ JAK2 inhibition, apoptosis-inducing activity, and molecular modelling studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109268"}}